Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
15.47
-0.38 (-2.40%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Mesoblast Revenue
Mesoblast had revenue of $51.34M in the half year ending December 31, 2025, with 1,415.41% growth. This brings the company's revenue in the last twelve months to $65.38M, up 1,053.16% year-over-year. In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth.
Revenue (ttm)
$65.38M
Revenue Growth
+1,053.16%
P/S Ratio
29.23
Revenue / Employee
$807,210
Employees
81
Market Cap
1.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Galapagos NV | 1.31B |
| Ultragenyx Pharmaceutical | 673.00M |
| Zai Lab | 460.16M |
| Iovance Biotherapeutics | 263.50M |
| Stoke Therapeutics | 205.63M |
| Soleno Therapeutics | 190.41M |
| Day One Biopharmaceuticals | 158.18M |
| Nektar Therapeutics | 62.60M |
MESO News
- 10 days ago - Mesoblast (MESO) Reports Significant Miss in 1H Earnings - GuruFocus
- 10 days ago - Mesoblast Limited (MESO) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 10 days ago - Half Year 2026 Mesoblast Ltd Earnings Presentation Transcript - GuruFocus
- 10 days ago - Ryoncil® Profits Underpinning Substantial Growth Pipeline - GlobeNewsWire
- 12 days ago - What's Next: Mesoblast's Earnings Preview - Benzinga
- 17 days ago - Mesoblast Financial Results and Corporate Update Webcast - GlobeNewsWire
- 25 days ago - Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy - Benzinga
- 25 days ago - Mesoblast Touts High Survival Rates For FDA-Approved Cell Therapy - Benzinga